10x Genomics Beats Earnings, Shares Drop

10x Genomics exceeded Wall Street expectations in their Q1 2026 earnings, reporting $150.8 million in revenue (down 2.6% YoY) and a loss of just $0.10 per share (better than the expected $0.29 loss). Adjusted operating income was positive at $5.6 million, surpassing forecasts. Despite matching full-year revenue guidance, investors pushed shares down 5.4% due to slowing growth and expected losses in the next year. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d990146ebecc41d4